The EMPOWER-Lung 1 trial assessed the efficacy and safety of cemiplimab in frontline advanced NSCLC with PD-L1 expression ≥50% and included 68 (12.1%) treated brain metastases patients (39). The gene discussed is CD274; the disease is non-small cell lung carcinoma.